New Technology Could Mitigate Post-Operative Atrial Fibrillation

preclinical research study from the Texas Heart Institute further validated a new technology developed by NativeCardio designed to mitigate postoperative atrial fibrillation (POAF): a critical condition that often manifests after cardiovascular, thoracic, and abdominal surgery, with ultra-low energy cardioversion.

“The Center for Preclinical Surgical & Interventional Research’s mission is to advance the understanding and treatment of cardiovascular disease. Our uniquely qualified staff of physicians and researchers have unequaled preclinical experience, and this collaboration with biomedical companies like NativeCardio is a lead example to conceive, design, test, and apply new treatments, techniques, and devices to improve patient care,” says Dr. Elgalad, the principal investigator for the study and the Co-Director of the Center for Preclinical Surgical & Interventional Research at THI

NativeCardio participated in the prestigious TMC Accelerator program (TMCx) 2020 Fall Bootcamp and consulted with the THI research team.

As a long-standing and active member institution of the Texas Medical Center, the Texas Heart Institute collaborates in several different ways across the TMC, the world’s largest medical center in the world, to help inventors and innovators advance promising treatments that could one day reduce impact patient suffering. To that end, there is no better resource to be found for a blossoming cardiac care startup than the collective brainpower at the Texas Heart Institute, which has been pushing the boundaries of cardiovascular research and education for 60 years.

“Texas Heart Institute can be a critical resource for cardiovascular-oriented startups —like NativeCardio — participating in accelerator programs,” says cardiologist and cardiac electrophysiologist Dr. Mehdi Razavi, Director of THI’s Department of Electrophysiology Clinical Research & Innovations. “These innovators need the input of leading physician experts in both the preclinical and clinical spaces, and our clinicians are enthusiastic about engaging with with them.”

Read News Story

Atrial Fibrillation Study by NativeCardio and the Texas Heart Institute Show Ultra-Low Cardioversion is Possible

Read the Study

Elgalad A, Moctezuma-Ramirez A, de Oliveira Cardoso C, John M, Pergolizzi J, Wolf RK. Ultra-low energy cardioversion in a pig model of atrial fibrillation: A feasibility study. Heart Rhythm. 2022 Jan 20:S1547-5271(22)00093-5. doi: 10.1016/j.hrthm.2022.01.023. Epub ahead of print. PMID: 35066182.